Expert Interviews

William Grady, MD, coauthor of the ECLIPSE trial, discusses how the Shield cfDNA blood-based test compares to traditional CRC screening methods.

COPD expert MeiLan K Han, MD, MS, says that in the absence of a definitive single tool to assess for COPD, probing patients for risk factors and symptoms is essential.

William Grady, MD, highlights the convenience and compliance of blood-based tests compared to colonoscopy and stool-based tests for colorectal cancer screening.

Cardiovascular comorbidities in adults with COPD are linked to poor outcomes including reduced QoL, increased hospitalizations, and greater risk of mortality, Han explains.

Michael Crotty, MD, an expert in obesity medicine, discusses GLP-1RAs in the context of weight loss, including the novel dual agonist survodutide.

Professor MeiLan Han, MD, MS, details inclusion of the 2 new medications and how the additions reflect a focus on disease heterogeneity and precision medicine in in COPD.

Geriatric psychiatrist and neurocognitive researcher George Grossberg, MD, highlights the mechanism of action for the new dextromethorphan/bupropion combination.

"It's a very rich pipeline because [agitation] is a very common and very debilitating symptom in Alzheimer's disease," Grossberg observed.

William Grady, MD, coauthor of the ECLIPSE clinical trial, discusses the study's rationale, methods, and key findings.

Antipsychotic medications are still used to treat potentially harmful acute agitation, George Grossberg, MD, explains, even though the adverse effects are well known.